The research examines the potential of predictive biomarkers, including PD-L1, Tumor Mutational Burden, Microsatellite Instability, and the microbiome, to guide personalized immunotherapy to enhance the efficacy of immunotherapies across many cancer types.
M. Yousefi, M. Farahpour, Nazila Alizadeh et al.· Discover Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.